Description
Packaging
60 tab.
Pharmacological action
Hypoglycemic.
Glurenorm stimulates the production of insulin by beta cells of the pancreas.
Indications
Type 2 diabetes mellitus (non-insulin-dependent) in middle-aged and elderly patients with diet therapy failure.
Contraindications
Hypersensitivity (including to sulfonylurea derivatives or sulfonylamides), type 1 diabetes mellitus (insulin-dependent), diabetic acidosis, ketoacidosis, precoma, coma, pregnancy, breast-feeding.
Pregnancy and lactation
There are no data on the use of glycvidone in women during pregnancy and breastfeeding.
It is not known whether glycidone or its metabolites passes into breast milk. Pregnant women with diabetes need careful monitoring of plasma glucose concentrations. Taking oral antidiabetic drugs in pregnant women does not provide adequate control of the level of carbohydrate metabolism. Therefore, the use of the drug Glurenorm ® during pregnancy and lactation is contraindicated.
In the event of pregnancy or when planning pregnancy during the use of the drug Glyurenorm ®, the drug should be discontinued and switch to insulin.
Special instructions
Glurenorm should not replace a therapeutic diet that allows you to control the patient ² ¢s body weight and reduce the risk of developing cardiovascular disorders.
Composition
1 tablet contains 30 mg glycvidone.
Excipients: lactose monohydrate – 134.6 mg, dried corn starch – 70 mg, soluble corn starch – 5 mg, magnesium stearate – 0.4 mg.
Method approxDenia and doses
The drug is administered orally. It is necessary to follow the doctor’s recommendations regarding the dose of the drug and diet. You should not stop taking the drug without consulting a doctor.
The initial dose of Glurenorm is usually 1/2 tab. (15 mg) at breakfast. The drug must be taken at the beginning of the meal. After taking Glurenorm, you should not skip a meal.
If reception 1/2 tab. (15 mg) does not lead to adequate improvement, after consulting a doctor, the dose should be gradually increased. If the daily dose of Glyurenorm does not exceed 2 tab. (60 mg), it can be prescribed in 1 dose, during breakfast.
When prescribing a higher dose, the best effect can be achieved by taking a daily dose divided into 2-3 doses. In this case, the highest dose should be taken at breakfast. Increase in a dose more than 4 tab. (120 mg) / day usually does not lead to a further increase in effectiveness.
The maximum daily dose is 4 tab. (120 mg).
Patients with impaired renal function
About 5% of the drug s metabolites are excreted by the kidneys. In patients with impaired renal function, dose adjustment is not required.
Patients with impaired liver function
Taking a dose exceeding 75 mg in patients with impaired liver function requires careful monitoring of the patient’s condition. The drug should not be prescribed to patients with severely impaired liver function, because 95% of the dose is metabolized in the liver and excreted through the intestines.
Combination therapy
In case of insufficient clinical effect of monotherapy with Glyrenorm ®, only additional administration of metformin may be recommended.
Side effects
From the hematopoietic system: thrombocytopenia, leukopenia, agranulocytosis.
Metabolism: hypoglycemia.
From the nervous system: headache, dizziness, drowsiness, paresthesia, feeling tired.
From the side of the organ of vision: disturbances in accommodation.
From the cardiovascular system: angina pectoris, extrasystole, cardiovascular failure, hypotension.
From the digestive system: loss of appetite, nausea, vomiting, constipation, diarrhea, discomfort in the abdomen, dry mouth, cholestasis.
From the skin and subcutaneous tissue: rash, itching, urticaria, Stevens-Johnson syndrome, photosensitivity reaction.
Other: chest pain.
Drug interaction
It is possible to enhance hypoglycemic action while prescribing glycvidone and ACE inhibitors, allopurinol, analgesics and NSAIDs, antifungal drugs, chloramphenicol, clarithromycin, clofibrate, coumarin sulfonate, hepharicin cyclin adenonate, hephosphonitrafoniforoniforoniforiforoniforoniforoniforiforoniforiforoniforiforoniforovniforonovoritovoritov, tiflorofilinfoniforoniforoniforoniforiforoniforiforoniforoniforidinovoriforoniforidinovorifovoritinov, triforuminiforoniforidiniforoniforifoniforidinovorifovorinovidiforodiniforodiniforodinovorif cyclophosphamide and its derivatives, insulin and oral hypoglycemic agents.
Beta-blockers, sympatholytics (including clonidine), reserpine and guanethidine can enhance the hypoglycemic effect and at the same time mask the symptoms of hypoglycemia.
It is possible to reduce the hypoglycemic effect while prescribing glycidone and aminoglutethimide, sympathomimetics, glucagon, thyroid hormones, glucagon, thiazide and loop diuretics, oral contraceptives, diazoxide, phenothiazine and drugs containing nicotinic acid.
Barbiturates, rifampicin, and phenytoin can also reduce the hypoglycemic effect of glycidone.
Strengthening or weakening of the hypoglycemic effect of glycidone has been described with histamine H2 receptor blockers (cimetidine, ranitidine) and ethanol.
Overdose
Overdose with sulfonylureas may lead to hypoglycemia.
Symptoms: tachycardia, increased sweating, feeling hungry, palpitations, tremors, headache, insomnia, irritability, impaired speech and vision, motor anxiety and loss of consciousness.
Treatment: In the event of symptoms of hypoglycemia, glucose (dextrose) or carbohydrate-rich foods should be taken. In severe hypoglycemia (loss of consciousness, coma), dextrose is introduced into / into. After regaining consciousness – the intake of easily digestible carbohydrates (to avoid the re-development of hypoglycemia).
Storage conditions
The product should be stored out of reach of children at a temperature not exceeding 25 ° C.
Shelf life
5 years.
Deystvuyushtee substance
gliquidone
Terms and conditions
prescription
dosage form
tablets
Possible product names
GLURENORM 0.03 N60 TABL
GLURENORM 30mg Tab. X60
GLURENORM 30mg No. 60
GLURENORM 30MG. No. 60 TAB.
Glurenorm tab. 30 mg x 60
Beringer Ingelyhaym, Austria
